PRKAA1 and metabolic dysfunction-associated steatotic liver disease: However, in the NAFLD + High-Rhein + AMPK-IN-3 group, this effect was markedly attenuated, with a rebound in body weight (P < 0.001), indicating that AMPK inhibition weakened the effect of Rhein.